Nominal interest rate

The effect of new housing supply in structural models: a forecasting performance evaluation

Retrieved on: 
Sunday, February 4, 2024
BET, Section 2, Model, XT, CIT, LTV, Forecasting, Total, Bank, RT, Elasticity, GDP, Website, University of Chicago Press, Process control block, Fiscal, Reproduction, University, WTP, Johns Hopkins University Press, E32, Faculty, Writing, KMR, Monetary economics, Household, Root mean square, YT, GFC, Language, VAR, A6, Motivation, Growth, PLT, Hartman–Grobman theorem, Research, House, Observation, Friction, Section 4, Classification, Macroeconomic model, BAA, AP, Kálmán, Odyssean Wicca, Parameter, Blue chip, A5, HPT, Mark Gertler, Learning, Smets, Inflation, ECB, Q2, Trade, CE, Hit, SPF, Review of Economic Dynamics, ZBW, Kolasa, LTM, R21, Patient, Prior, Shock, Movement, ZT, Australasian, M1, Lens, Great, Nobuhiro, European Central Bank, Estimator, Policy, LTI, COVID-19, Attention, HP, Feedback, Goethe University Frankfurt, International Journal of Forecasting, Federal Reserve, Federal Reserve Bank, Behavior, Health, Blue Chip Economic Indicators, Inverse, Zero lower bound, The Blue, Journal of Applied Econometrics, Economic forecasting, Matrix, Economy, Federal, R31, LTP, Chinese Blackjack, WTI, CES, Sim, Bit, Section 5, Capital market, Quantitative Economics, Credit, Motion, Central bank, Journal of Political Economy, Political economy, Taylor & Francis, Journal of Monetary Economics, Act, Binning, CPT, DPT, Point, MCMC, RealTime, Literature, Metropolis–Hastings algorithm, ZLB, TFP, Research Papers in Economics, Del Negro, GBT, Communication, Kalman filter, Markov, Cycle, Business cycle, Eurozone, DFF, PDF, Filter, Medical classification, American Economic Journal, Demand shock, Comparison, Employment, KTEH, Cobb–Douglas production function, Nonprofit organization, Sampler, PTW, Par, Liquidity trap, Paper, Nominal interest rate, QT, Exercise, Monetary policy, RTD, Interest rate, A7, University of Cambridge, Control, Statistics, Posterior, Pressure, American Economic Review, E37, Financial intermediary, Social science, Basel II, Delphic, Depreciation, European Economic Review, HPD, Ai, Calendar, E17, Government, Journal of Econometrics, HTM, Freedom, LTE, Probability, Face, Calibration, Oxford University Press, New Keynesian economics, Sun, HH, Me, Uncertainty, FPI, Production, Dynamics, Handbook, Real estate
Key Points: 

    New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023

    Retrieved on: 
    Thursday, January 19, 2023
    Oncology, Health, Surgery, Genetics, Research, Science, Biotechnology, American Society of Clinical Oncology, NPV, SCCA, Poster, ASCO, University, CRC, MRD, GI, Stomach, Fred Hutchinson Cancer Research Center, DNA, Sequence, Nucleic acid thermodynamics, Radiation oncologist, Anal cancer, NTRA, Nominal interest rate, Patient, Society, University of Washington School of Medicine, Pharmaceutical industry, Medical imaging, Medical device, Nature Medicine, Natera

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California.

    Key Points: 
    • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the American Society of Clinical Oncology's 2023 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 19 – 21, 2023 in San Francisco, California.
    • The presentations will highlight findings on the utility of Signatera for MRD assessment in colorectal (CRC), esophageal, gastric and anal cancers, in a total of five presentations.
    • “On the heels of the groundbreaking CIRCULATE-Japan results just released, we are excited to share additional data further underscoring the real-world utility of Signatera in GI cancers,” said Solomon Moshkevich, general manager of oncology at Natera.
    • Additionally, analysis of whole exome sequencing data from all 251 patients found significant genomic heterogeneity, further highlighting the value of a personalized and tumor-informed approach to ctDNA testing.

    Surgery First for Colon Cancer? Not So Fast, According to New Study in JNCCN

    Retrieved on: 
    Wednesday, January 11, 2023
    University, CRC, Colorectal cancer, Immunotherapy, National Comprehensive Cancer Network, Sun Yat-sen University Cancer Center, Safety, Surgeon, State Key Laboratories, University of Wisconsin Carbone Cancer Center, Sun, Financial toxicity, Neoplasm, NCCN, Nominal interest rate, Patient, Research, Cancer, PD-1, Recurrence, Pharmaceutical industry, MD

    PLYMOUTH MEETING, Pa., Jan. 11, 2023 /PRNewswire/ -- New research in the January 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). Nearly all of the patients studied benefitted from neoadjuvant PD-1 inhibitors, with 1-of-4 experiencing complete response on clinical assessment. In addition to the short-term effectiveness, the findings showed substantial longer survival benefits from neodjuvant PD-1 inhibitors, including a low recurrence rate when compared with historic rates.

    Key Points: 
    • Nearly all of the patients studied benefitted from neoadjuvant PD-1 inhibitors, with 1-of-4 experiencing complete response on clinical assessment.
    • Of those 73, 48 were diagnosed with colon cancer, 18 with rectal cancer, and 7 with multiple types of CRC.
    • The 2-year rates for tumor-specific overall survival and disease-free survival were 100% for patients who underwent surgery after PD-1 blockade.
    • The study had an average follow-up time of 17.2 months, with 16 patients tracked for more than two years.

    Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

    Retrieved on: 
    Tuesday, January 3, 2023
    Bone marrow, Genetic distance, Melphalan, NHLBI, SCD, Busulfan, Therapy, Nominal interest rate, Sickle cell disease, Phenotype, Toxicity, Alemtuzumab, Cellular, Patient, Thalassemia, Beta thalassemia, Physician, Safety, B cell, Transplant, Cell, Dentistry

    The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.

    Key Points: 
    • The addition of briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.
    • The Phase 1/2 clinical study is led by Dr. John F. Tisdale, Director of the Cellular and Molecular Therapeutics Laboratory, NHLBI.
    • Briquilimab has the potential to improve disease-free survival in combination with low-dose irradiation as part of a transplant conditioning regimen.
    • All three sickle cell study participants treated with briquilimab have successfully engrafted with no briquilimab-related severe adverse events observed.

    Amphera Announces Clinical Updates of MesoPher Cell Therapy

    Retrieved on: 
    Monday, December 12, 2022
    Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Recurrence, CT, European Journal, Patient, Cancer, OS, Injection, Nominal interest rate, Mesothelioma, BSC, Reactive, Neoplasm, Pancreatic cancer, Pharmaceutical industry

    Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today reports topline results from both the phase II Reactive trial and the phase II/III DENIM trial.

    Key Points: 
    • Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today reports topline results from both the phase II Reactive trial and the phase II/III DENIM trial.
    • In the phase II Reactive trial, patients with resected pancreatic cancer who had completed standard-of-care chemotherapy received 3 bi-weekly injections of Ampheras MesoPher dendritic cell therapy and booster injections at 4 and 7 months.
    • Further randomized clinical research with MesoPher in pancreatic cancer is a likely next step.
    • MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines.

    Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid Biopsies with Machine Learning

    Retrieved on: 
    Tuesday, December 6, 2022
    Biotechnology, Technology, Health, Pharmaceutical, Oncology, Research, Software, Artificial Intelligence, Genetics, Science, Clinical Trials, Prognosis, NGS, Diagnosis, GTC, Algorithm, Software, Degenerative disease, Transcriptome, Society, Health, Biomarker, Patient, DNA, Science, CFRNA, American Society of Hematology, LCA, Somatic mutation, Transplant, Nominal interest rate, Lymphoid neoplasms with plasmablastic differentiation, Nucleic acid thermodynamics, Artificial intelligence, Bone marrow, Cooperative, Machine learning, The, Lymphatic system, RNA, ASH, Primary central nervous system lymphoma, Birth control, Medical device

    GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.

    Key Points: 
    • GTC continues to demonstrate the superior capabilities of their new cell-free (cfDNA) and cell-free RNA (cfRNA) liquid biopsy test called Liquid Trace.
    • Using cfRNA, GTC studies show that the cfRNA levels can be used in liquid immunoprofiling of hematologic neoplasms.
    • Combining this liquid immunophenotyping with machine learning algorithms report high reliability in the differential diagnosis between various types of lymphoid neoplasms/lymphoma.
    • The use of RNA profiling in tissue and liquid biopsies is opening new horizons in diagnostics, especially when combined with artificial intelligence.

    Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology

    Retrieved on: 
    Tuesday, December 6, 2022
    The Lancet, Monarch butterfly migration, Recurrence, Cohort, Eli Lilly and Company, EBC, Ki-67, Patient, ET, Royal Marsden Hospital, NYSE, Breast cancer, Disease, Breast cancer classification, ALN, NHS foundation trust, Woman, Nominal interest rate, Death, ITT, The Royal Marsden NHS Foundation Trust, Risk, Pharmaceutical industry, Abemaciclib

    INDIANAPOLIS, Dec. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC). These data, which include results for investigational uses in the intent-to-treat (ITT) and Cohort 1 populations, were presented today as an oral presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in The Lancet Oncology.

    Key Points: 
    • The monarchE trial (N=5,637) included women and men with HR+, HER2-, node-positive EBC with a high risk of disease recurrence.
    • Adjuvant Verzenio also reduced the risk of developing metastatic disease by 34.1% (HR=0.659, 95% CI: 0.567, 0.767; nominal p
    • Data presented at SABCS also included efficacy outcomes in the FDA-approved population, as well as the Cohort 1 population.
    • Nearly twice as many patients in the control arm have developed and are living with metastatic disease compared to those receiving Verzenio.

    PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

    Retrieved on: 
    Monday, November 14, 2022
    Trial of the century, Communication, Survival, Neck, Lymph, National Cancer Institute, Type 1, CT scan, Cancer, Mayo Clinic, Disease, Radiation, PDS, Toxicity, Immunotherapy, Treatment, Vaccine, Cervical cancer, Blood, Partnership, PET, University, Neoplasm, Research, Nature, Society, MD Anderson Cancer Center, Biotechnology, COVID-19, Merck & Co., Vulvar cancer, Warfarin necrosis, NCI, Merck, MRI, Human, CD8, Sharp, Nominal interest rate, Clinical professor, Therapy, FIGO, CRT, CPI, Gamma ray, III, Risk, Infection, Merck Sharp & Dohme Federal Credit Union, PDSB, Positron emission tomography, CR, Head, SITC, Pharmaceutical industry, Medical imaging, Patient

    FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial was presented during a poster session on November 11 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer (SITC 2022). These data expand upon results detailed in the abstract submitted to SITC 2022 that was released to the public on November 7.

    Key Points: 
    • This includes 78% (7/9) of treated patients with advanced cervical cancer (FIGO stage III or IV).
    • 100% (9/9) of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.
    • We look forward to the continued advancement of the IMMUNOCERV Phase 2 clinical trial and the opportunity to report updated data during 2023.
    • A third Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer is being led by The University of Texas MD Anderson Cancer Center.

    NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

    Retrieved on: 
    Thursday, November 10, 2022
    FDA, Infectious Diseases, Health, Clinical Trials, Oncology, Review, Private Securities Litigation Reform Act, Cancer, Forward-looking statement, Pembrolizumab, NEJM, Vaccine, Treatment of lung cancer, BCG, Severe acute respiratory syndrome coronavirus 2, Pancreatic cancer, Cystectomy, Food, Immunotherapy, CR, Breakthrough therapy, Incidence, Population, CRS, BLA, COVID-19, DFS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SEC, Medicine, Fast Track, TURBT, Patient, U.S. Securities and Exchange Commission, Infection, CIS, Large-cell lung carcinoma, Probability, Disease, NAI, Clinical trial, Maintenance, NK, GMP, Immune system, Progression-free survival, Nominal interest rate, HIV, FDA, Trial of the century, Pharmaceutical industry, ImmunityBio, NMIBC, FDA, Infectious Diseases, Health, Clinical Trials, Oncology

    NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease.

    Key Points: 
    • NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease.
    • Patients with intermediate or high-risk NMIBC typically receive a treatment of transurethral resection of the bladder tumor (TURBT) followed by BCG intravesical instillation.
    • However, cancer will recur in 30% to 40% of patients with NMIBC despite adequate treatment with BCG.
    • Moreover, even among those in whom a complete response is achieved with BCG, up to 50% see their cancer return.

    Profound Improvement for Pancreatic Cancer Patients Using CivaSheet®, a New Radiation Device

    Retrieved on: 
    Thursday, November 3, 2022
    Oncology, Medical Devices, Health, Clinical Trials, General Health, Radiology, Doctor of Philosophy, Patient, Neoplasm, Loyola University, Virginia Commonwealth University, VCU Massey Cancer Center, Recurrence, Multimedia, SBIR, Radiation, Death, Quality of life, Pancreatic cancer, VCU, University of Connecticut Health Center, Nominal interest rate, Disease, SBRT, Toxicity, Survival, Pharmaceutical industry, Engineered wood, Medical imaging

    CivaTech Oncology Inc., announces CivaSheet significantly boosts outcomes for borderline resectable and locally advanced pancreatic cancer patients.

    Key Points: 
    • CivaTech Oncology Inc., announces CivaSheet significantly boosts outcomes for borderline resectable and locally advanced pancreatic cancer patients.
    • CivaSheet, an implantable, targeted, shielded radiation device delivers an aggressive dose immediately to the pancreas region following surgical resection.
    • These data are strongly compelling and demonstrate significant impact on the increased survival of pancreatic cancer patients, commented Suzanne Babcock, Chairman of CivaTech Oncology.
    • Patients have no device related toxicity and report a better quality of life without having disease recurrence and subsequent treatment.